公开(公告)号：US20160128363A1

公开(公告)日：2016-05-12

申请号：US14895397

申请日：2014-06-04

申请人： John W. FINLEY ,  Thomas GETTYS ,  Frank L. GREENWAY

发明人： John W. Finley ,  Thomas Gettys ,  Frank L. Greenway

IPC分类号： A23L1/015

CPC分类号： A23L5/25 ,  A23G9/32 ,  A23K20/147 ,  A23L2/66 ,  A23L5/27 ,  A23L5/276 ,  A23L7/109 ,  A23L7/196 ,  A23L13/40 ,  A23L13/50 ,  A23L15/30 ,  A23L19/12 ,  A23L33/10 ,  A23L33/17 ,  A23L33/175 ,  A23L33/19 ,  A23L33/30 ,  A23L33/40 ,  A23V2002/00 ,  A23V2200/328 ,  A23V2200/332 ,  A23V2250/0632 ,  A23V2250/54246

摘要： A method is disclosed for making palatable methionine-restricted foods, to deliver a methionine-restricted diet to human or veterinary patients. A protein or a food product containing protein is partially oxidized, preferably with ozone, to oxidize nearly all of the methionine and cysteine. After oxidation, tryptophan and lysine are optionally added back since they tend to be oxidized also. Optionally, a small amount of methionine is also added back so that the final methionine is within a preferred range of about 0.85 to about 1.8 gram methionine per 100 gram total protein, preferably about 1.2 gram per 100 gram total protein.

摘要翻译： 公开了一种制备可食用甲硫氨酸限制食品的方法，以将甲硫氨酸限制性饮食递送给人或兽医患者。 蛋白质或含有蛋白质的食品部分被氧化，优选用臭氧氧化几乎所有的甲硫氨酸和半胱氨酸。 氧化后，任选地加入色氨酸和赖氨酸，因为它们也倾向于被氧化。 任选地，还加入少量的甲硫氨酸，使得最终甲硫氨酸在每100克总蛋白质约0.85至约1.8克甲硫氨酸的优选范围内，优选约1.2克/ 100克总蛋白质。

公开(公告)号：US10897921B2

公开(公告)日：2021-01-26

申请号：US14895397

申请日：2014-06-04

申请人： John W. Finley ,  Thomas Gettys ,  Frank L. Greenway

发明人： John W. Finley ,  Thomas Gettys ,  Frank L. Greenway

IPC分类号： A23L5/20 ,  A23G9/32 ,  A23L2/66 ,  A23K20/147 ,  A23L13/50 ,  A23L33/00 ,  A23L33/10 ,  A23L33/175 ,  A23L7/109 ,  A23L7/196 ,  A23L33/17 ,  A23L19/12 ,  A23L13/40 ,  A23L15/00 ,  A23L33/19

摘要： A method is disclosed for making palatable methionine-restricted foods, to deliver a methionine-restricted diet to human or veterinary patients. A protein or a food product containing protein is partially oxidized, preferably with ozone, to oxidize nearly all of the methionine and cysteine. After oxidation, tryptophan and lysine are optionally added back since they tend to be oxidized also. Optionally, a small amount of methionine is also added back so that the final methionine is within a preferred range of about 0.85 to about 1.8 gram methionine per 100 gram total protein, preferably about 1.2 gram per 100 gram total protein.

公开(公告)号：US5224175A

公开(公告)日：1993-06-29

申请号：US519223

申请日：1990-05-07

申请人： James O. Gouge ,  Thomas Gettys

发明人： James O. Gouge ,  Thomas Gettys

IPC分类号： A61B8/00 ,  G06T1/00 ,  G06T7/00 ,  G06T7/40

CPC分类号： G06T7/403 ,  G06K9/46 ,  G06T7/0012 ,  G06K2209/053 ,  G06T2207/10132 ,  G06T2207/20104 ,  G06T2207/30096

摘要： A method and device for interpreting and processing medical ultrasound and other video images. The mix of reflection coefficients in pixel windows is measured by determining the range and distribution of pixel gray scale values to establish "echoic texture" characteristics. These characteristics are compared with corresponding characteristics of known tissues. The degree of correlation allows a prediction of tissue characteristics of the examined window.

摘要翻译： 一种用于解释和处理医用超声波和其他视频图像的方法和装置。 通过确定像素灰度值的范围和分布来确定“回波纹理”特征来测量像素窗口中的反射系数的混合。 将这些特征与已知组织的相应特征进行比较。 相关度允许预测检查窗口的组织特征。

公开(公告)号：US5830434A

公开(公告)日：1998-11-03

申请号：US806203

申请日：1997-02-26

申请人： Ian L Taylor ,  Thomas Gettys

发明人： Ian L Taylor ,  Thomas Gettys

IPC分类号： A61K38/22 ,  A61K49/00 ,  A61K38/08 ,  A61K38/28

CPC分类号： A61K38/22 ,  A61K38/28 ,  A61K49/0004 ,  A61K31/155 ,  A61K31/18 ,  Y10S435/81 ,  Y10S514/866

摘要： The present invention provides a method of treating NIDDM in a patient diagnosed with NIDDM by administering to the patient a compound in a pharmaceutically acceptable carrier that reduces hepatic glucose production in the patient by inhibiting hepatic expression of the alpha subunit of a G.sub.s protein in a liver cell plasma membrane, thereby inhibiting stimulation of cAMP by glucagon, whereby the reduction in hepatic glucose production treats the NIDDM. Also provided is a method for screening compounds for the ability to treat NIDDM comprising determining if the compound decreases hepatic expression of the alpha subunit of a G.sub.s protein in a liver cell plasma membrane, thereby inhibiting the stimulation of cAMP by glucagon, a compound which decreases the hepatic expression of the alpha subunit of the G.sub.s protein in the liver cell plasma membrane, thereby inhibiting the stimulation of cAMP by glucagon, being a compound with the ability to treat NIDDM. The present invention further provides a kit for treating NIDDM comprising a compound in a pharmaceutically acceptable carrier that decreases hepatic expression of the alpha subunit of the G.sub.s protein in the liver cell plasma membrane, thereby inhibiting stimulation of cAMP by glucagon.

摘要翻译： 本发明提供一种通过向患者施用药物可接受的载体中的化合物来治疗患有NIDDM的患者中的NIDDM的方法，其通过抑制肝脏中Gs蛋白的α亚基的肝表达来降低患者的肝葡萄糖产生 细胞质膜，从而抑制胰高血糖素对cAMP的刺激，由此肝葡萄糖产生的减少治疗NIDDM。 还提供了筛选化合物治疗NIDDM能力的方法，包括确定该化合物是否降低肝细胞质膜中Gs蛋白的α亚基的肝表达，由此抑制由胰高血糖素，降低的化合物刺激cAMP 在肝细胞质膜中Gs蛋白的α亚基的肝表达，从而抑制由胰高血糖素刺激cAMP，这是具有治疗NIDDM能力的化合物。 本发明还提供了用于治疗NIDDM的试剂盒，其包含药学上可接受的载体中的化合物，其降低肝细胞质膜中Gs蛋白的α亚基的肝表达，由此抑制胰高血糖素刺激cAMP。